Switzerland's Economic Recovery Gains Momentum Despite Global Challenges

Switzerland's economic outlook has brightened significantly after a challenging year marked by US tariffs, supply chain disruptions, and a strong Swiss franc. The threat of a 39% tariff on Swiss exports to the US was reduced to 15% after negotiations and investment pledges by Swiss firms. Despite ongoing challenges, Swiss firms showed remarkable adaptability, driving real GDP growth of 1.5% in the second quarter of 2026, the fastest pace in nearly five years. This recovery was led by chemical and pharmaceutical sectors, along with a rise in global tech-led investment.

The country's strong fundamentals, including low inflation and healthy public finances, provide a buffer against global macroeconomic headwinds. Headline inflation reached 1.0% year-on-year in September, but is expected to remain below 1% into 2027. The Swiss National Bank (SNB) is unlikely to raise its policy rate from 0%, contrasting with other central banks tightening monetary policy. The Swiss franc has weakened slightly, with forecasts predicting a 0.83 exchange rate for USDCHF and 0.95 for EURCHF over the next 12 months.

Swiss equity valuations have returned to historic averages, with selective opportunities in world-class companies operating in stable economic and political environments. Healthcare and financials dominate the Swiss Market Index, but tariff risks persist, particularly for the pharmaceutical sector. The country faces longer-term challenges, including an ageing population and the need for increased productive investment to support long-term growth. Public referendums on population caps and neutrality were recently voted down, reflecting Switzerland's adaptability in a changing world order.